Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in the Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at 9:00 a.m. Pacific Time. The company, known for its mRNA medicines and vaccines, will discuss its pipeline focused on vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A webcast of the presentation will be available on the company's investor relations website.

Founded in 2013, Arcturus continues to innovate in RNA therapeutics with extensive patent coverage.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.

A webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005237/en/

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@ArcturusRx.com

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When will Arcturus Therapeutics present at the J.P. Morgan Healthcare Conference?

Arcturus Therapeutics will present at the J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. Pacific Time.

What is the focus of Arcturus Therapeutics' presentation at the conference?

The presentation will focus on Arcturus' pipeline in mRNA medicines and vaccines for infectious diseases and rare diseases.

Where can I watch the Arcturus Therapeutics conference presentation?

You can watch the Arcturus presentation via webcast on the Investor Relations section of their website.

What is Arcturus Therapeutics known for?

Arcturus Therapeutics is known for its late-stage clinical development of mRNA medicines and vaccines, including candidates for COVID-19 and other diseases.

What technologies does Arcturus Therapeutics utilize?

Arcturus uses technologies such as LUNAR lipid-mediated delivery and STARR mRNA Technology in its therapeutic development.